Weight Loss with Glutaric Aciduria Type 2 (MADD) in South Africa

Glutaric Aciduria Type 2 (GA2) — also called Multiple Acyl-CoA Dehydrogenase Deficiency (MADD) — is a rare fatty acid and amino acid oxidation disorder that affects multiple metabolic pathways simultaneously. Unlike the more focused enzyme defects in MCAD, VLCAD, or LCHAD Deficiency, MADD disrupts the entire electron transfer chain from acyl-CoA dehydrogenase enzymes to the respiratory chain. If you or someone in your care has been diagnosed with MADD and is looking to manage body weight, this guide explains the biochemistry, the dietary boundaries, which cases respond to riboflavin (vitamin B2) supplementation, and how to safely approach a caloric deficit under metabolic team supervision in South Africa.

What Is Glutaric Aciduria Type 2 (MADD)?

The beta-oxidation of fatty acids and the catabolism of several amino acids both produce electrons that are transferred via FADH2 to coenzyme Q10 in the mitochondrial respiratory chain. This electron transfer does not happen directly — it is mediated by two electron transfer flavoproteins:

ETF accepts electrons from multiple acyl-CoA dehydrogenases — the enzymes that perform the first step of beta-oxidation at different chain lengths (SCAD, MCAD, LCAD, VLCAD, isovaleryl-CoA dehydrogenase, glutaryl-CoA dehydrogenase, and others). ETF:QO then transfers these electrons to coenzyme Q10.

When ETFA, ETFB, or ETFDH is mutated, all the upstream acyl-CoA dehydrogenases effectively lose their electron acceptor. The result is a simultaneous block in:

This breadth of blocked pathways explains why MADD produces a striking acylcarnitine profile — elevated C4, C5, C6, C8, C10, C12, C14, C16, and C5-DC acylcarnitines simultaneously — unlike single-enzyme defects that show elevation at a specific chain length.

In urine organic acid analysis, multiple organic acids are elevated: glutaric, ethylmalonic, adipic, suberic, 2-hydroxyglutaric, isovalerylglycine, isobutyrylglycine, and others — hence the alternative name "multiple acyl-CoA dehydrogenase deficiency."

MADD Severity Spectrum: Three Phenotypes

MADD presents across a wide severity range:

Riboflavin-Responsive MADD: A Critical Distinction

One of the most important features of MADD — particularly late-onset ETFDH-related disease — is that a substantial proportion of patients respond dramatically to high-dose riboflavin (vitamin B2) supplementation. Riboflavin is the precursor of FAD (flavin adenine dinucleotide), which is the cofactor for ETF and ETF:QO. In some ETFDH mutations, the protein is structurally intact but has reduced affinity for FAD. Saturating the enzyme with supraphysiological riboflavin concentrations restores partial to near-complete function.

Clinical response to riboflavin in responsive patients can be dramatic:

Riboflavin dose for MADD typically ranges from 100–400 mg per day (far above the normal 1.3–1.6 mg dietary reference intake). This is a therapeutic dose prescribed by your metabolic team after confirming the diagnosis and ideally after confirming an ETFDH mutation. Self-prescribing high-dose riboflavin without a confirmed MADD diagnosis is not appropriate.

If you have MADD and have not yet been assessed for riboflavin responsiveness, this is a critical conversation to have with your metabolic team — a positive response fundamentally changes your dietary restrictions and quality of life.

Dietary Management in MADD

Dietary management in MADD depends critically on phenotype severity and riboflavin responsiveness:

Severe Neonatal Phenotypes (Types I and II)

Management parallels fatty acid oxidation disorder protocols:

Late-Onset MADD (Riboflavin-Responsive Type III)

For the milder adult phenotype that is riboflavin-responsive, dietary fat restriction is often substantially less stringent:

Your specific dietary prescription must come from your metabolic team based on your phenotype, genotype, riboflavin response, and current clinical status. The variation between patients is too large for a single universal diet.

Weight Loss in MADD: Phenotype-Specific Approaches

Severe MADD (Neonatal-Onset Survivors)

Late-Onset MADD (Type III, Riboflavin-Responsive)

SA Practical Food Guide for MADD Weight Management

Monitoring During Weight Loss

Metabolic follow-up in South Africa is available at major academic hospitals. For adults, the inherited metabolic disease clinic at Charlotte Maxeke Johannesburg Academic Hospital or the metabolic unit at Red Cross War Memorial Children's Hospital (if transitioning to adult care) are the primary referral centres. Riboflavin-responsive MADD may also be managed by a neurologist experienced in metabolic myopathies.

Summary

MADD (Glutaric Aciduria Type 2) is a heterogeneous disorder with management that varies dramatically by phenotype and riboflavin responsiveness. For late-onset riboflavin-responsive patients, weight loss is achievable with a 300–500 kcal/day deficit through fat moderation and carbohydrate portion control, alongside continued riboflavin supplementation and L-carnitine if prescribed. For severe phenotypes, any caloric deficit must be minimal and medically supervised. The critical differentiator is whether your specific ETFDH (or ETFA/ETFB) mutation responds to riboflavin — if you have not been formally assessed for riboflavin responsiveness, this should be the first conversation with your metabolic team. Never stop riboflavin supplementation without medical guidance, avoid large high-fat meals, and monitor CK as a proxy for muscle stress during dietary changes. Always consult your metabolic physician and dietitian before making any dietary changes.

This article is for informational purposes only and does not constitute medical advice. All dietary management for Glutaric Aciduria Type 2 / MADD must be supervised by a qualified metabolic physician and dietitian.